Posted by Michael Wonder on 06 May 2025
Rezolute receives breakthrough therapy designation from FDA for ersodetug in the treatment of hypoglycaemia due to tumour hyperinsulinism
5 May 2025 - Registrational study in patients with tumour hyperinsulinism expected to commence mid-year.
Rezolute today announced that the US FDA has granted breakthrough therapy designation to its investigational therapy, ersodetug, for the treatment of hypoglycemia caused by tumour hyperinsulinism.
